Funds Say Valeant Price-Gouging Probe Cost Them $80B
Valeant Pharmaceuticals International Inc.'s alleged price-gouging scheme cost shareholders more than $80 billion once the scheme came to light, investors said in a suit filed in New Jersey district court Tuesday....To view the full article, register now.
Already a subscriber? Click here to view full article